Marek Vargovčák1, Erik Dorko2, Kvetoslava Rimárová2, Viliam Knap3. 1. Urological Outpatient Clinic, Railway Hospital, Kosice, Slovak Republic. 2. Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic. 3. Department of Physiatry, Balneology, and Medical Rehabilitation, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic.
Abstract
OBJECTIVE: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options. METHODS: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated. RESULTS: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients. CONCLUSION: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.
OBJECTIVE: Prostate adenocarcinoma (CaP) is one of the most common malignancies in men in Slovakia and in the world. The disease accounts for more than 22% of all tumors in the male population. Screening studies show an increase in the diagnosis of CaP without improvement in overall or CaP-specific mortality. The main goal of the work is to evaluate the incidence of CaP in the group of patients examined and treated during the period from 2014 to 2019 at the urological outpatient clinic of the Railway Hospital (RH) in Košice, and to evaluate the risks and treatment options. METHODS: Men aged 40 to 75 years underwent a preventive examination in 2014-2019 at the urology outpatient clinic, RH Košice. The number of screened patients was 3,943. Epidemiological parameter, diagnosis-related examinations (prostate specific antigen - PSA examination, digital rectal examination, and ultrasonography examination) as well as the frequency of examinations were monitored during the specified period on the basis of documentation. The number of prostate biopsies, incidence of prostate cancer and relation to PSA values were also monitored, as well as the classification of prostate cancers according to the degree of risk. Initial treatment in individual patients was also evaluated. RESULTS: PSA values in patients who underwent biopsy ranged from 3.6 ng/mL to 2,000 ng/mL. We observed positive digital rectal examination in 52 patients. Of the number of patients examined, 231 (61.28%) were positive biopsies. There were negative biopsies with the finding of benign prostatic hyperplasia in 92 patients or chronic prostatitis in 54 patients, i.e., 146 (38.72%). According to the criteria for risk assessment based on the PSA value and the result of the histological examination, we diagnosed 109 low-risk patients, 57 medium-risk patients and 24 high-risk patients. CONCLUSION: CaP is detected by prevention about 10 years before it develops clinically. The main aim of preventive examinations should be to detect, in particular, high-risk forms of early-stage prostate cancer and to improve the quality of life of men. Due to the results of extensive studies, it is necessary to continue the active search for prostate cancer. This reduces the risk of metastatic forms of CaP.
Entities:
Keywords:
conservative treatment; prevention and health promotion; prostate cancer; prostate cancer management; quality of life
Authors: Daniël F Osses; Sebastiaan Remmers; Fritz H Schröder; Theo van der Kwast; Monique J Roobol Journal: Eur Urol Date: 2018-11-09 Impact factor: 20.096
Authors: Jonas Hugosson; Monique J Roobol; Marianne Månsson; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Sigrid V Carlsson; Kirsi M Talala; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Donella Puliti; Arnauld Villers; Xavier Rebillard; Tuomas P Kilpeläinen; Ulf H Stenman; Rebecka Arnsrud Godtman; Karin Stinesen Kollberg; Sue M Moss; Paula Kujala; Kimmo Taari; Andreas Huber; Theodorus van der Kwast; Eveline A Heijnsdijk; Chris Bangma; Harry J De Koning; Fritz H Schröder; Anssi Auvinen Journal: Eur Urol Date: 2019-02-26 Impact factor: 20.096
Authors: Martijn Smeenge; Jelle Barentsz; David Cosgrove; Jean de la Rosette; Theo de Reijke; Scott Eggener; Ferdinand Frauscher; Gyoergy Kovacs; Surena F Matin; Massimo Mischi; Peter Pinto; Ardeshir Rastinehad; Olivier Rouviere; Georg Salomon; Thomas Polascik; Jochen Walz; Hessel Wijkstra; Michael Marberger Journal: BJU Int Date: 2012-03-30 Impact factor: 5.588
Authors: E A M Heijnsdijk; T M de Carvalho; A Auvinen; M Zappa; V Nelen; M Kwiatkowski; A Villers; A Páez; S M Moss; T L J Tammela; F Recker; L Denis; S V Carlsson; E M Wever; C H Bangma; F H Schröder; M J Roobol; J Hugosson; H J de Koning Journal: J Natl Cancer Inst Date: 2014-12-13 Impact factor: 13.506
Authors: Monique J Roobol; Ewout W Steyerberg; Ries Kranse; Tineke Wolters; Roderick C N van den Bergh; Chris H Bangma; Fritz H Schröder Journal: Eur Urol Date: 2009-09-01 Impact factor: 20.096
Authors: Thomas B L Lam; Steven MacLennan; Peter-Paul M Willemse; Malcolm D Mason; Karin Plass; Robert Shepherd; Ruud Baanders; Chris H Bangma; Anders Bjartell; Alberto Bossi; Erik Briers; Alberto Briganti; Karel T Buddingh; James W F Catto; Maurizio Colecchia; Brett W Cox; Marcus G Cumberbatch; Jeff Davies; Niall F Davis; Maria De Santis; Paolo Dell'Oglio; André Deschamps; James F Donaldson; Shin Egawa; Christian D Fankhauser; Stefano Fanti; Nicola Fossati; Giorgio Gandaglia; Silke Gillessen; Nikolaos Grivas; Tobias Gross; Jeremy P Grummet; Ann M Henry; Alexandre Ingels; Jacques Irani; Michael Lardas; Matthew Liew; Daniel W Lin; Lisa Moris; Muhammad Imran Omar; Karl H Pang; Catherine C Paterson; Raphaële Renard-Penna; Maria J Ribal; Monique J Roobol; Morgan Rouprêt; Olivier Rouvière; Gemma Sancho Pardo; Jonathan Richenberg; Ivo G Schoots; J P Michiel Sedelaar; Phillip Stricker; Derya Tilki; Susanne Vahr Lauridsen; Roderick C N van den Bergh; Thomas Van den Broeck; Theodorus H van der Kwast; Henk G van der Poel; Geert J L H van Leenders; Murali Varma; Philippe D Violette; Christopher J D Wallis; Thomas Wiegel; Karen Wilkinson; Fabio Zattoni; James M O N'Dow; Hendrik Van Poppel; Philip Cornford; Nicolas Mottet Journal: Eur Urol Date: 2019-10-03 Impact factor: 20.096